Osamu Nureki
Gründer bei MODALIS THERAPEUTICS CORPORATION
Vermögen: 994 999 $ am 31.05.2024
Aktive Positionen von Osamu Nureki
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MODALIS THERAPEUTICS CORPORATION | Direktor/Vorstandsmitglied | 01.01.2016 | - |
Gründer | 01.01.2016 | - | |
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Direktor/Vorstandsmitglied | 01.11.2019 | - |
University of Tokyo | Corporate Officer/Principal | 01.04.2008 | - |
Karriereverlauf von Osamu Nureki
Ausbildung von Osamu Nureki
University of Tokyo | Graduate Degree |
Statistik
International
Japan | 4 |
Operativ
Director/Board Member | 2 |
Founder | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MODALIS THERAPEUTICS CORPORATION | Health Technology |
Private Unternehmen | 1 |
---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |
- Börse
- Insiders
- Osamu Nureki
- Erfahrung